TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Immunovia AB ( (SE:IMMNOV) ) has shared an announcement.
Immunovia AB has reported a successful third quarter in 2025, highlighted by the launch of its PancreaSure test, which aims to enhance early detection of pancreatic cancer. The company noted a reduction in cash burn and operating losses, aligning with expectations, and received strong interest from key opinion leaders in the U.S. The PancreaSure test has been validated by the scientific community and is making strides towards Medicare reimbursement, positioning Immunovia as a leader in pancreatic cancer diagnostics. Additionally, the company secured manufacturing independence and achieved a successful rights issue, strengthening its financial position.
More about Immunovia AB
Immunovia AB is a company focused on the early detection of pancreatic cancer, primarily through its innovative diagnostic tests. The company operates within the healthcare industry, with a market focus on improving cancer diagnostics and patient outcomes.
Average Trading Volume: 9,146,393
Technical Sentiment Signal: Sell
Current Market Cap: SEK169M
See more data about IMMNOV stock on TipRanks’ Stock Analysis page.